Bloomberg News

Siga Shouldn’t Have to Pay PharmAthene Over Drug, Lawyer Says

By Phil Milford
January 10, 2013

Siga Technologies Inc. (SIGA) shouldn’t have to hand over 50 percent of the profits from a smallpox medicine to rival PharmAthene Inc. (PIP), lawyers for the drugmaker told an appeals court today.

To contact the reporter on this story: Phil Milford in Wilmington, Delaware at pmilford@bloomberg.net

To contact the editor responsible for this story: Andrew Dunn at adunn8@bloomberg.net

Business Exchange: What your peers are reading.

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

blog comments powered by Disqus